# SpyGlass Pharma Inc. (SGP) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Health Care Technology. Price $28.94, market value $968 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). SpyGlass Pharma Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 3.9×**. The shares trade at 3.9× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -4.7%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: 40.3%**. 40.3% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.

## Growth
- **EPS growth (1 yr): -10.2%**. Earnings per share fell 10.2%.

## Financial health
- **Current ratio: 12.67** (quick 12.67). Current assets cover the next year's liabilities 12.67 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. SpyGlass Pharma Inc. does not currently pay a dividend.

## Price and momentum
- **From 52-week high: -10.8%** (69.6% above the low). Trading 11% below its 52-week high.
- **RSI (14-day): 72**. An RSI of 72 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 1.58** (volatility 64%). Beta of 1.58 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=SGP · Page: https://foliofundamentals.com/stocks/sgp

Not investment advice.